Hsbc Holdings PLC Avrobio, Inc. Transaction History

Hsbc Holdings PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.64 - $0.91 $176 - $251	-276 Reduced 1.64%	16,556 $11,000
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $1,261 - $2,059	-1,855 Reduced 9.93%	16,832 $11,000
Q4 2021 Feb 11, 2022	BUY	$3.45 - $6.05 $64,470 - $113,056	18,687 New	18,687 $71,000
Q1 2021 May 14, 2021	SELL	$10.54 - $19.3 $171,053 - $313,219	-16,229 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$12.79 - $17.1 $207,568 - $277,515	16,229 New	16,229 $226,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.